TEVA PHARMACEUTICAL INDUSTRIES LTD
corporate_fare Company Profile
TEVA PHARMACEUTICAL INDUSTRIES LTD (NYSE:TEVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for TEVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for TEVA spans 8-K, FWP, 424B5, 10-Q.
Recent high-impact activity:
- Teva Slides 7% as R&D Chief Eric Hughes Exits Mid-Pivot
- Teva R&D Chief Eric Hughes Resigns Immediately; Gardiner Named Transition Lead
- Teva Wins FDA Nod for At-Home Use of Igalmi in Schizophrenia Agitation
- Teva Targets $6-7B Innovative Medicine Revenue by 2030, Backs It With $10B Pipeline
- Teva Beats Q3 Estimates, Lifts 2026 Revenue and EPS Outlook
Financial Snapshot
Short Interest & Short Volume
5.30 days to coverFINRA reported short interest of 27,739,194 shares in TEVA as of the October 30, 2026 settlement, a 1.2% decrease from the prior period — about 5.3 days to cover at its recent average daily volume. On November 20, 2026, 23.0% of TEVA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.